Plitidepsin
Contraindications- Product Name
- Plitidepsin
- CAS No.
- 137219-37-5
- Chemical Name
- Plitidepsin
- Synonyms
- Aplidin;Plitidepsin;Plitidepsin top3;cyclic peptide deriv.;Plitidepsin (Aplidine);Didemnin A, N-(1-(1,2-dioxopropyl)-L-prolyl)-;2-9-Didemnin B, 2-(1-(1,2-dioxopropyl)-L-proline)-;Inhibitor,DNA/RNA Synthesis,MOLT-4,SARS coronavirus,infection,SARS-CoV,Plitidepsin,Leukemia,VEGF,COVID-19,Antiviral,inhibit,Aplidine,advanced cancer,anticancer,Advanced Malignancies;3,6-Anhydro-(N-{(2S,4S)-4-[(3S,4R,5S)-3-hydroxy-4-{[N-(2-oxo-propanoyl)-L-prolyl-N-Methyl-D-leucyl-L-threonyl]aMino}-5-Methyl-heptanoyloxy]-2,5-diMethyl-3-oxohexanoyl}-L-leucyl-L-prolyl-N;L-Tyrosine, 1-(1,2-dioxopropyl)-L-prolyl-N-methyl-D-leucyl-L-threonyl-(3S,4R,5S)-4-amino-3-hydroxy-5-methylheptanoyl-(2S,4S)-4-hydroxy-2,5-dimethyl-3-oxohexanoyl-L-leucyl-L-prolyl-N,o-dimethyl-, (8-3)-lactone
- CBNumber
- CB11508609
- Molecular Formula
- C57H87N7O15
- Formula Weight
- 1110.34
- MOL File
- 137219-37-5.mol
Plitidepsin Property
- Melting point:
- 152-160°
- alpha
- D -95.9° (c = 1.8 in CHCl3)
- Density
- 1.24±0.1 g/cm3(Predicted)
- storage temp.
- -20°C
- solubility
- DMSO: soluble
- pka
- 11.28±0.70(Predicted)
- form
- Solid
- color
- White to off-white
- InChIKey
- UUSZLLQJYRSZIS-NIORUGPLNA-N
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Danger
- Hazard statements
-
H225Highly Flammable liquid and vapour
H319Causes serious eye irritation
- Precautionary statements
-
P210Keep away from heat/sparks/open flames/hot surfaces. — No smoking.
P233Keep container tightly closed.
P240Ground/bond container and receiving equipment.
P241Use explosion-proof electrical/ventilating/lighting/…/equipment.
P242Use only non-sparking tools.
P243Take precautionary measures against static discharge.
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P264Wash hands thoroughly after handling.
P264Wash skin thouroughly after handling.
P270Do not eat, drink or smoke when using this product.
P271Use only outdoors or in a well-ventilated area.
P280Wear protective gloves/protective clothing/eye protection/face protection.
P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P303+P361+P353IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304+P340IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
P321Specific treatment (see … on this label).
P330Rinse mouth.
P337+P313IF eye irritation persists: Get medical advice/attention.
P370+P378In case of fire: Use … for extinction.
P403+P235Store in a well-ventilated place. Keep cool.
P501Dispose of contents/container to..…
N-Bromosuccinimide Price
- Product number
- API0005125
- Product name
- APLIDINE
- Purity
- 95.00%
- Packaging
- 5MG
- Price
- $499.63
- Updated
- 2021/12/16
Plitidepsin Chemical Properties,Usage,Production
Contraindications
Hypersensitivity to the active substance, plitidepsin, or to the excipients PEG-35 castor oil or ethanol.
Description
Plitidepsin is a cyclic depsipeptide that was first isolated from a Mediterranean marine tunicate (Aplidium albicans) and, at present, is manufactured by total synthesis and commercialized as Aplidin?. Its antitumor activity, observed in preclinical in vitro and in vivo studies has prompted numerous clinical trials to be conducted over the last 17 years, alone or in combination with other anticancer agents.
Definition
ChEBI: Plitidepsin is a didemnin that is didemin B in which the hydroxy group of the 1-(2-hydroxypropanoyl)-L-prolinamide moiety has been oxidised to the corresponding ketone. It was originally isolated from the Mediterranean tunicate Aplidium albicans. It has a role as a marine metabolite, an antineoplastic agent and an anticoronaviral agent.
Biological Activity
Plitidepsin is a cytotoxic peptide originally found in the sea squirt Aplidium albicans. It interacts with a protein (eEF1A2) which is overexpressed in some cancers. This interaction leads to apoptosis. Synthetically produced plitidepsin has been found to have antiproliferative effects on cancer cells. Phase II trials have investigated its activity in tumours such as lung cancer, melanoma and multiple myeloma.
Mechanism of action
Plitidepsin induces apoptosis in multiple myeloma cells, which involves activation of p38 and c-jun NH(2)-terminal kinase signaling, Fas/CD95 translocation to lipid rafts, and ultimately caspase activation. The investigational agent also decreases the proliferation of multiple myeloma cells, an effect mediated by the suppression of several proliferative genes.In a pivotal phase III trial of patients with relapsed or refractory multiple myeloma, plitidepsin in combination with dexamethasone (Dex) significantly reduced the risk of progression or death compared to Dex alone.Plitidepsin has been approved by TGA in Australia for the treatment of multiple myeloma in combination with dexamethasone for patients that relapse after three lines of treatment, including proteasome inhibitors or immunomodulators.
Clinical Use
Plitidepsin is a cyclic depsipeptide isolated from the marine tunicate Aplidium albicans. Plitidepsin displays a broad spectrum of antitumor activities, inducing apoptosis by triggering mitochondrial cytochrome c release, initiating the Fas/ DC95, JNK pathway and activating caspase 3 activation. This agent also inhibits elongation factor 1-a, thereby interfering with protein synthesis, and induces G1 arrest and G2 blockade, thereby inhibiting tumor cell growth.A phase II prospective open-label study (Ferme et al. 2008 ) to evaluate its activity in patients with relapsed/ refractory non-cutaneous PTCL was conducted in 14 patients. They were treated with plitidepsin 3.2 mg/m 2 IV infusion over 1-h on days 1, 8 and 15 every 4 weeks. Eleven patients were evaluable when preliminary results were reported, one was too early and two were non-evaluable. One con fi rmed CR and 3 PR’s were observed with a 36% objective response rate. Median overall survival was 11 months.
Plitidepsin was tolerable in this heavily pretreated population with low hematological toxicity. Transient but reversible ALT elevation was noticed in 7 patients.
Future trials will establish its role in T-cell lymphoma.
Safety Profile
Plitidepsin's safety profile has been extensively studied over both phase I and II/III trials, with the drug presenting mostly transient and tolerated adverse events. Myalgia, alanine aminotransferase/aspartate aminotransferase, creatine phosphokinase increase, fatigue, nausea, and vomiting constituted the most common dose-limiting toxicities in phase I studies. The same adverse events were reported regarding phase II/III studies, along with mild to moderate hematologic abnormalities, such as anaemia and thrombocytopenia. A hypersensitivity reaction was also observed; the event was well-tolerated, except one patient was withdrawn from a trial due to a grade 4 hypersensitivity reaction and hypotension. Notably, plitidepsin with dexamethasone was related to less hepatic enzyme abnormalities compared to plitidepsin alone, while a study assessing the combination of plitidepsin with dexamethasone and bortezomib reported no dose-limiting adverse events[1].
in vitro
In vitro studies have demonstrated that plitidepsin has anti-myeloma activity against 19 multiple myeloma cell lines including cells resistant to anti-myeloma agents frequently used in the clinic (i.e. melphalan, doxorubicin, thalidomide derivatives, and dexamethasone) and primary multiple myeloma cells isolated from patients (13 out 16 showed a response to plitidepsin).
References
[1] Michail Papapanou. “Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19.” Journal of Personalized Medicine (2021).
Plitidepsin Preparation Products And Raw materials
Raw materials
Preparation Products
Plitidepsin Suppliers
- Tel
- 021-50872116 13611907556
- Fax
- 021-31300828
- contact@fuxinpharm.com
- Country
- China
- ProdList
- 1596
- Advantage
- 58
- Tel
- 021-021-52919136 17315815539
- 2804155403@qq.com
- Country
- China
- ProdList
- 205
- Advantage
- 58
- Tel
- 0512-58900862 400-0707518
- Fax
- 0086-512-56765862
- sales@alabiochem.com
- Country
- China
- ProdList
- 995
- Advantage
- 59
- Tel
- 021-61551611 13296011611
- Fax
- ＋86 21-50676805
- contact@trustwe.com
- Country
- China
- ProdList
- 9895
- Advantage
- 58
- Tel
- 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
- Fax
- +86-27-87599188
- Country
- China
- ProdList
- 1493
- Advantage
- 55
- Tel
- 18149758185 18149758185
- sales-cpd@caerulumpharma.com
- Country
- China
- ProdList
- 3466
- Advantage
- 58
- Tel
- 028-81700200 18116577057
- Fax
- 028-81705658
- 3003855609@qq.com
- Country
- China
- ProdList
- 7887
- Advantage
- 56
- Tel
- 0576-84613060 13093829633
- Fax
- 0576-84613060
- sales@kedechemical.com
- Country
- China
- ProdList
- 298
- Advantage
- 60
- Tel
- +86-21-5821 5861
- Fax
- +86-21-5106 2861
- sales@letopharm.com
- Country
- China
- ProdList
- 2384
- Advantage
- 58
- Tel
- 21-619849051-1 18521059765
- synchempharma@aliyun.com
- Country
- China
- ProdList
- 6463
- Advantage
- 55
- Tel
- Fax
- -
- eric_feng1954@126.com
- Country
- China
- ProdList
- 9248
- Advantage
- 55
- Tel
- 021-65675885 18964387627
- Fax
- 021-65675885
- info@efebio.com
- Country
- China
- ProdList
- 9806
- Advantage
- 58
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8014
- Advantage
- 62
- Tel
- 021-2022843681 15618226720
- Fax
- +86-21-51601218
- chaolaichem@foxmail.com
- Country
- China
- ProdList
- 7539
- Advantage
- 58
- Tel
- 027-59402396 13419635609
- Fax
- 027-83989310
- 13419635609@163.com
- Country
- China
- ProdList
- 1992
- Advantage
- 55
- Tel
- 027-027-83778875 15807197853
- Fax
- 027-83991220
- 15807197853@163.com
- Country
- China
- ProdList
- 4009
- Advantage
- 58
- Tel
- +86-15542445688
- Fax
- 0086-411-39042693
- sales@alabiochem.com
- Country
- China
- ProdList
- 888
- Advantage
- 58
- Tel
- 027-83778895 18602735115
- Fax
- 027-51119224
- 18602735115@163.com
- Country
- China
- ProdList
- 1991
- Advantage
- 64
- Tel
- 0411-39042497
- Fax
- 0411-39042693
- sales@alphabiopharm.com
- Country
- China
- ProdList
- 1951
- Advantage
- 58
- Tel
- +86-18339805032; +8618339805032
- alfa4@alfachem.cn
- Country
- China
- ProdList
- 13227
- Advantage
- 58
- Tel
- +86-0571-81612335 +8613336028439
- sales@nextpeptide.com
- Country
- China
- ProdList
- 19908
- Advantage
- 58
- Tel
- +86-0571-85134551
- Fax
- 008657185134895
- sales@afinechem.com
- Country
- China
- ProdList
- 15357
- Advantage
- 58
- Tel
- 008613515763466 8615669048680
- wendy@huidabiotech.com
- Country
- CHINA
- ProdList
- 87
- Advantage
- 58
- Tel
- 021-58447131 13564518121
- sales@dcchemicals.com
- Country
- China
- ProdList
- 9410
- Advantage
- 58
- Tel
- +86-021-61551413 +8618813727289
- contact@trustwe.com
- Country
- China
- ProdList
- 5738
- Advantage
- 58
- Tel
- 027-027-52344656 15871722230
- Fax
- 2796190295
- 15871722230@163.com
- Country
- China
- ProdList
- 4710
- Advantage
- 58
- Tel
- 0571-88760729 18072970094
- supports@ontorespeptide.com
- Country
- China
- ProdList
- 2696
- Advantage
- 58
- Tel
- 0571-89903882 13626641628
- jiangnan@huidabiotech.com
- Country
- China
- ProdList
- 3656
- Advantage
- 58
- Tel
- 18051384581
- sales@chemhifuture.com
- Country
- China
- ProdList
- 3056
- Advantage
- 58
- Tel
- 027-59101668 19945030958
- Fax
- 027-59101668
- 2881924765@qq.com
- Country
- China
- ProdList
- 8140
- Advantage
- 58
- Tel
- 17362916295 17362916295
- Fax
- QQ:840947394
- w17362916295@163.com
- Country
- China
- ProdList
- 3022
- Advantage
- 58
- Tel
- 0571-0571-89903882 15990081639
- sunshixuan@huidabiotech.com
- Country
- China
- ProdList
- 3705
- Advantage
- 58
- Tel
- 13549236410
- sales@invivochem.cn
- Country
- China
- ProdList
- 6753
- Advantage
- 58
- Tel
- 400-880-2824 15608648206
- 1987516016@qq.com
- Country
- China
- ProdList
- 2772
- Advantage
- 58
- Tel
- +86-027-59232304 15387063101
- 2881924050@qq.com
- Country
- China
- ProdList
- 9989
- Advantage
- 58
- Tel
- 027-59222918 13385289472
- Z13385289472@163.com
- Country
- China
- ProdList
- 4565
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24648
- Advantage
- 58
- Tel
- 18671296875
- 1205035102@qq.com
- Country
- China
- ProdList
- 4302
- Advantage
- 58
- Tel
- 17362916295; 17362916295
- w17362916295@163.com
- Country
- China
- ProdList
- 4046
- Advantage
- 58
- Tel
- 13720134139 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 5793
- Advantage
- 58
- Tel
- 13296077563 13296077563
- hr@bettersyn.com
- Country
- China
- ProdList
- 9932
- Advantage
- 58
- Tel
- 17721492509
- 643638326@qq.com
- Country
- China
- ProdList
- 5345
- Advantage
- 58
- Tel
- 13823398779 18670069958
- 313359644@qq.com
- Country
- China
- ProdList
- 3263
- Advantage
- 58
- Tel
- 027-59102966 18717199209
- 2853877583@QQ.com
- Country
- China
- ProdList
- 7026
- Advantage
- 58
- Tel
- 027-02759101766 13125137661
- 2853877621@qq.com
- Country
- China
- ProdList
- 5191
- Advantage
- 58
- Tel
- 18024082417
- market@ubiochem.com
- Country
- China
- ProdList
- 9272
- Advantage
- 58
- Tel
- 155-71556913 15571556913
- 354024111@qq.com
- Country
- China
- ProdList
- 2408
- Advantage
- 58
- Tel
- +undefined-21-51877795
- Fax
- +86 21 5161 9052/ 5187 7796
- ivan@atkchemical.com
- Country
- China
- ProdList
- 32820
- Advantage
- 60
- Tel
- +8613817748580
- Fax
- 021-50175322
- cooperation@kean-chem.com
- Country
- China
- ProdList
- 40066
- Advantage
- 58
- Tel
- +8613720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 5221
- Advantage
- 58
View Lastest Price from Plitidepsin manufacturers
- Product
- Plitidepsin 137219-37-5
- Price
- US $8.00-0.80/kg
- Min. Order
- 1kg
- Purity
- 99%
- Supply Ability
- g-kg-tons, free sample is available
- Release date
- 2024-04-08
- Product
- Plitidepsin 137219-37-5
- Price
- US $998.00/mg
- Min. Order
- 1mg
- Purity
- 97%
- Supply Ability
- 10mg
- Release date
- 2021-05-07